Identification of signal transduction pathways involved in constitutive NF-κB activation in breast cancer cells

[1]  Eric Verdin,et al.  Duration of Nuclear NF-κB Action Regulated by Reversible Acetylation , 2001, Science.

[2]  Michael Karin,et al.  Activation by IKKα of a Second, Evolutionary Conserved, NF-κB Signaling Pathway , 2001, Science.

[3]  E. Lander,et al.  Growth Factor-specific Signaling Pathway Stimulation and Gene Expression Mediated by ErbB Receptors* 210 , 2001, The Journal of Biological Chemistry.

[4]  Marty W. Mayo,et al.  Akt Stimulates the Transactivation Potential of the RelA/p65 Subunit of NF-κB through Utilization of the IκB Kinase and Activation of the Mitogen-activated Protein Kinase p38* , 2001, The Journal of Biological Chemistry.

[5]  D. Seldin,et al.  Roles of IKK kinases and protein kinase CK2 in activation of nuclear factor-kappaB in breast cancer. , 2001, Cancer research.

[6]  H. Nakshatri,et al.  Repression of GADD153/CHOP by NF-κB: a possible cellular defense against endoplasmic reticulum stress-induced cell death , 2001, Oncogene.

[7]  W. Yung,et al.  Tumor Suppressor MMAC/PTEN Inhibits Cytokine-induced NFκB Activation without Interfering with the IκB Degradation Pathway* , 2001, The Journal of Biological Chemistry.

[8]  C. Gélinas,et al.  Regulation of death receptor expression and TRAIL/Apo2L-induced apoptosis by NF-κB , 2001, Nature Cell Biology.

[9]  R. Ratan,et al.  The Epidermal Growth Factor Receptor Engages Receptor Interacting Protein and Nuclear Factor-κB (NF-κB)-inducing Kinase to Activate NF-κB , 2001, The Journal of Biological Chemistry.

[10]  A. Baldwin.  Control of oncogenesis and cancer therapy resistance by the transcription factor NF-κB , 2001 .

[11]  R. Steele,et al.  Deceiving appearances: signaling by “dead” and “fractured” receptor protein‐tyrosine kinases , 2000, BioEssays : news and reviews in molecular, cellular and developmental biology.

[12]  Yosef Yarden,et al.  Molecular mechanisms underlying ErbB2/HER2 action in breast cancer , 2000, Oncogene.

[13]  G. Sledge,et al.  Paclitaxel sensitivity of breast cancer cells with constitutively active NF-κB is enhanced by IκBα super-repressor and parthenolide , 2000, Oncogene.

[14]  G. Sledge,et al.  Cancer cell-derived interleukin 1alpha contributes to autocrine and paracrine induction of pro-metastatic genes in breast cancer. , 2000, Biochemical and biophysical research communications.

[15]  S. Mader,et al.  Heregulin selectively upregulates vascular endothelial growth factor secretion in cancer cells and stimulates angiogenesis , 2000, Oncogene.

[16]  Debajit K. Biswas,et al.  Epidermal growth factor-induced nuclear factor κB activation: A major pathway of cell-cycle progression in estrogen-receptor negative breast cancer cells , 2000 .

[17]  Monilola A. Olayioye,et al.  The ErbB signaling network: receptor heterodimerization in development and cancer , 2000, The EMBO journal.

[18]  J. Russo,et al.  Activation of NF-kappaB/Rel occurs early during neoplastic transformation of mammary cells. , 2000, Carcinogenesis.

[19]  Richard W. E. Clarkson,et al.  NF-κB Inhibits Apoptosis in Murine Mammary Epithelia* , 2000, The Journal of Biological Chemistry.

[20]  M. Hung,et al.  HER-2/neu Blocks Tumor Necrosis Factor-induced Apoptosis via the Akt/NF-κB Pathway* , 2000, The Journal of Biological Chemistry.

[21]  W. Funkhouser,et al.  Selective activation of NF-κB subunits in human breast cancer: potential roles for NF-κB2/p52 and for Bcl-3 , 2000, Oncogene.

[22]  T. Gilmore,et al.  Control of apoptosis by Rel/NF-κB transcription factors , 1999, Oncogene.

[23]  B. Rayet,et al.  Aberrant rel/nfkb genes and activity in human cancer , 1999, Oncogene.

[24]  M. Sliwkowski,et al.  Biologic effects of heregulin/neu differentiation factor on normal and malignant human breast and ovarian epithelial cells , 1999, Oncogene.

[25]  L. Pfeffer,et al.  NF-κB activation by tumour necrosis factor requires the Akt serine–threonine kinase , 1999, Nature.

[26]  C. Van Waes,et al.  The host environment promotes the constitutive activation of nuclear factor-kappaB and proinflammatory cytokine expression during metastatic tumor progression of murine squamous cell carcinoma. , 1999, Cancer research.

[27]  G. Stark,et al.  Activation of Phosphatidylinositol 3-Kinase in Response to Interleukin-1 Leads to Phosphorylation and Activation of the NF-κB p65/RelA Subunit , 1999, Molecular and Cellular Biology.

[28]  H. Nakshatri,et al.  Negative Regulation of Transactivation Function but Not DNA Binding of NF-κB and AP-1 by IκBβ1 in Breast Cancer Cells* , 1999, The Journal of Biological Chemistry.

[29]  N. Maihle,et al.  Isolation and characterization of four alternate c-erbB3 transcripts expressed in ovarian carcinoma-derived cell lines and normal human tissues , 1998, Oncogene.

[30]  S. Ghosh,et al.  Phosphorylation of NF-kappa B p65 by PKA stimulates transcriptional activity by promoting a novel bivalent interaction with the coactivator CBP/p300. , 1998, Molecular cell.

[31]  D. Cortez,et al.  A requirement for NF-κB activation in Bcr–Abl-mediated transformation , 1998 .

[32]  P. W. Janes,et al.  Analysis of Grb7 Recruitment by Heregulin-activated erbB Receptors Reveals a Novel Target Selectivity for erbB3* , 1998, The Journal of Biological Chemistry.

[33]  P. Leder,et al.  Signal transduction pathways activated and required for mammary carcinogenesis in response to specific oncogenes , 1998, Oncogene.

[34]  D. Stern,et al.  Specificity within the EGF family/ErbB receptor family signaling network , 1998, BioEssays : news and reviews in molecular, cellular and developmental biology.

[35]  G. Evan,et al.  Induction of TNF‐sensitive cellular phenotype by c‐Myc involves p53 and impaired NF‐κB activation , 1997, The EMBO journal.

[36]  B. Dörken,et al.  Constitutive nuclear factor-kappaB-RelA activation is required for proliferation and survival of Hodgkin's disease tumor cells. , 1997, The Journal of clinical investigation.

[37]  A. E. Rogers,et al.  Aberrant nuclear factor-kappaB/Rel expression and the pathogenesis of breast cancer. , 1997, The Journal of clinical investigation.

[38]  A. Richmond,et al.  Enhanced Degradation of I-κBα Contributes to Endogenous Activation of NF-κB in Hs294T Melanoma Cells , 1997 .

[39]  G. Sledge,et al.  Constitutive activation of NF-kappaB during progression of breast cancer to hormone-independent growth , 1997, Molecular and cellular biology.

[40]  Marty W. Mayo,et al.  TNF- and Cancer Therapy-Induced Apoptosis: Potentiation by Inhibition of NF-κB , 1996, Science.

[41]  M. Hung,et al.  Suppressed transformation and induced differentiation of HER-2/neu-overexpressing breast cancer cells by emodin. , 1995, Cancer research.

[42]  C. Der,et al.  Aberrant function of the Ras signal transduction pathway in human breast cancer , 1995, Breast Cancer Research and Treatment.

[43]  R. Lidereau,et al.  Genetic alteration of the c-myc protooncogene (MYC) in human primary breast carcinomas. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[44]  R. Roeder,et al.  Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei. , 1983, Nucleic acids research.

[45]  M J May,et al.  NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses. , 1998, Annual review of immunology.